Clinical Trial Update: Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA CAR-NK Cell Injection for the Treatment of Refractory Pediatric Rheumatic Diseases [EARLY_Phase 1]

View source ↗

Summary

An early phase 1 exploratory trial is assessing the safety and potential efficacy of anti-CD19/BCMA CAR-NK cell injections for refractory pediatric rheumatic di…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Arthritis
• Connective Tissue Disease-associated Interstitial Lung Disease
• Kawasaki Disease
• Rheumatic Diseases
• Systemic Lupus Erythematosus

Drugs mentioned

• CAR-NK cell therapy targeting CD19 and BCMA

Snippet

Sponsor: The Children's Hospital of Zhejiang University School of Medicine | Conditions: Rheumatic Diseases, Pediatric Rheumatological Condition (i.e., Arthritis, SLE, Kawasaki's Disaese) | EARLY_Phase 1 | Status: RECRUITING